BLOG: Bayesian Longitudinal Omics with Group Constraints

Livia Popa, Sumanta Basu, Myung Hee Lee, Martin T. Wells · 2025

Read BLOG: Bayesian Longitudinal Omics with Group Constraints by Livia Popa, Sumanta Basu, Myung Hee Lee, Martin T. Wells (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/arxiv-2505-11673.txt.

Introduction

Livia Popa, Sumanta Basu, Myung Hee Lee, and Martin Wells present statistical methods in two thousand twenty-five for finding biomarkers in omics data. Clinical teams increasingly hunt for markers in short-term repeated measurements, where uncertainty and false discovery must be controlled. Their toolkit, BLOG, is Bayesian and built for such longitudinal data.

One approach scores single variables with a special prior and Bayes factors, with two ways to set its tuning value. A second approach selects whole groups of variables with a group lasso and spike-and-slab prior. Both work on changes between time points. Tests on simulated data and a tuberculosis metabolite study picked the right markers with high accuracy. The methods beat standard mixed models.

Catalog record

CREATORLivia Popa, Sumanta Basu, Myung Hee Lee, Martin T. Wells
YEAR2025
COLLECTIONPAPERS
FORMATTXT
FILE SIZE57 KB
VERSION1.0
LICENSEhttp://creativecommons.org/licenses/by/4.0/
RIGHTSCC BY
SOURCEarXiv

Source: https://arxiv.org/abs/2505-11673

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

BLOG: Bayesian Longitudinal Omics with Group Constraints Livia Popa, Sumanta Basu, Myung Hee Lee, Martin T. Wells Abstract Clinical investigators are increasingly interested in discovering computational biomarkers from short-term longitudinal omics data sets. This work focuses on Bayesian regression and variable selection for longitudinal omics datasets, which can quantify uncertainty and control false discovery. In our univariate approach, Zellner’s g g prior is used with two different options of the tuning parameter g g : g = n g=\sqrt{n} and a g g that minimizes Stein’s unbiased risk estimate (SURE). Bayes Factors were used to quantify uncertainty and control for false discovery. In the multivariate approach, we use Bayesian Group LASSO with a spike and slab prior for group variable selection. In both approaches, we use the first difference ( Δ \Delta ) scale of longitudinal predictor and the response. These methods work together to enhance our understanding of biomarker identification, improving inference and prediction. We compare our method against commonly used linear mixed effect models on simulated data and real data from a Tuberculosis (TB) study on metabolite biomarker selection. With an automated selection of hyperparameters, the Zellner’s g g prior approach correctly identifies target metabolites with high specificity and sensitivity across various simulation and real data scenarios. The Multivariate Bayesian Group Lasso spike and slab approach also correctly selects target metabolites across various simulation scenarios. 1 Introduction Clinical investigators have become increasingly interested in collecting data on a large number of omics features in order to build computational biomarkers that can predict the clinical outcome. These predictions can serve as indirect indicators of disease progression and can provide new information about physiological processes [ 9 , 7 , 17 ] . Existing methods in the high-dimensional setting use penalized regression and do not offer uncertainty quantification. This work focuses on Bayesian high-dimensional regression and variable selection for longitudinal omics datasets, which can quantify uncertainty, control for false discovery, and addresses the limited power in short-term longitudinal studies. To address the challenges of high-dimensional longitudinal omics data, we present two complementary Bayesian approaches—one univariate and one multivariate. The univariate method offers interpretable, marginal evidence for individual biomarker associations, while the multivariate method captures joint effects and correlation structures across features. Presenting both approaches in a single framework provides versatile tools for clinical investigators that are tailored to different inference goals and study designs such as identifying individual associations or capturing joint effects across features. By operating on the first difference scale, the projected model effectively controls for time-invariant heterogeneity and captures dynamic biomarker-outcome associations over time. These extensions use uncertainty quantification and mixed-effects modeling using a combination of Bayesian regression and regularization. This work makes significant methodological contributions to the analysis of high-dimensional longitudinal omics data, with direct relevance to biomarker discovery. This work is motivated by two clinical trial studies. The first is a study of tuberculosis consisting of 4 time point observations for 15 subjects each with a measured mycobacterial load of the sputum, quantified by the time in hours to the positivity of Mtb culture (TTP), and abundances of up to 915 urinary metabolites. We also evaluated our method in an intensive lifestyle intervention study aimed at understanding the underlying reversible causes of diabetes among patients [ 25 ] . This study contained 5 time point observations for 16 subjects, each with measured change in three outcomes (HDL, I2GDF15, and I2MIC1) and 17 protein abundances. Previous work has been performed on the identification of metabolite-based biomarkers for patients with tuberculosis [ 5 , 14 , 30 ] and the identification of biomarkers affecting diabetic patients [ 24 , 13 ] . Existing work in the clinical omics literature uses univariate longitudinal predictive regression models [ 27 , 28 ] for the outcome of interest. In order to select significant variables, these methods compare p-values across univariate models. These models lack consideration for correlations of features over time which leads to reduced sensitivity and reduced statistical power. The literature on high-dimensional omics in molecular biology and genomics is vast, but these methods are not designed around using a time-varying clinical outcome to guide variable selection. The most common method for analyzing such data sets is linear mixed-effects model to regress clinical outcomes on one or more feature trajectories, but these methods are often not powerful enough unless data is collected over a moderate time horizon. More recently, the PROLONG (Penalized regression on longitudinal omics data with network and group constraints) method was proposed [ 5 ] , which can jointly select longitudinal features that co-vary with a time-varying outcome on the first difference scale. This method leverages correlation between variable trajectories by using the first-difference scale, which controls for time dependence within the data. This improves power and eliminates the need for time-related assumptions. PROLONG also introduces network and group lasso constraints to induce sparsity, while also grouping different time components of each metabolite and incorporating the correlation structure of the data. The current version of PROLONG does not offer uncertainty quantification, which is important for precisely controlling false discoveries and assessing the statistical significance of biomarkers. This work focuses on uncertainty quantification and controlling for false discovery using Bayesian high-dimensional regression and variable selection for longitudinal omics datasets. In the Bayesian setting, we adopt an empirical Bayesian approach as well as hierarchical Bayes principles for hyperparameter selection. In the univariate setting, Zellner-g prior is used to generate posterior distributions to obtain Bayes factors to quantify uncertainty. Two choices of g are considered to highlight the trade-off between empirical optimality and practical performance. The first choice being one that minimizes Stein’s unbiased risk estimate (SURE), offering data-driven calibration, while the second, g=\sqrt{n} ,has shown strong empirical performance and competitive variable selection behavior comparable to LASSO. Including both allows us to assess robustness across different prior specifications and offers practical guidance for clinical investigators. Bayes factors were then calculated for both choices of g using a Bayes factor proposed in [ 18 ] . More details are given in the Methods Section 3 . In the multivariate case, we use a Bayesian formulation of Group LASSO with spike and slab priors [ 31 ] . This procedure uses a multivariate point mass mixture similar to Zhang et al. (2014) [ 34 ] that facilitates the selection of group variables by producing exact 0 estimates at the group level. We evaluated this method using posterior mean thresholding, which can select and estimate variables at the same time. To validate these methods, we simulate target and noise variables using different signal-to-noise ratios and compare them to the following benchmark methods presented in the PROLONG paper: Linear Mixed Effect model (LME) p-values and the Univariate PROLONG Wald test p-values 4.1 . We find that the univariate model correctly identifies target variables from noise and quantifies uncertainty by giving significant Bayes factors based on thresholding described in Section 3 . We also find that the univariate method is able to identify significant metabolites from the TB data and give corresponding significant Bayes factors compared to the PROLONG Wald tests. The univariate method can also identify proteins of interest to clinical investigators when applied to diabetes data 5 . For the multivariate method,

Read the complete text